Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

NCT04147533 is registered in ClinicalTrials.gov with Masaryk University as lead sponsor.

NCT NCT04147533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04147533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission
Lead sponsor
Masaryk University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 16, 2020
Completion date
June 30, 2026
Enrollment
150 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase, withdrawal;drug